Curtana Pharmaceuticals is a pioneering brand dedicated to developing highly targeted therapies for brain cancer. With a focus on glioblastoma in adults and medulloblastoma in children, Curtana aims to revolutionize the treatment of these aggressive types of brain cancers. Unlike current options that offer limited hope, Curtana is advancing a groundbreaking small molecule therapy, CT-179, which has shown promising results in extending survival in animal models.

This therapy targets Olig2, a crucial cancer stem cell-associated transcription factor that drives tumor initiation and growth. Curtana has submitted an Investigational New Drug Application to the FDA and has received a Study May Proceed letter, as well as Fast Track designation. The company plans to commence a Phase 1 clinical trial in glioblastoma patients soon.

With its strong commitment to patient safety and generating necessary clinical trial data, Curtana is determined to bring their investigational product to market for widespread availability. Learn more about their innovative approach and CT-179, the first highly targeted, potent, small molecule inhibitor of Olig2